ClinicalTrials.gg
CompletedNCT01484431Updated Oct 9, 2019Results posted

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

A Phase 1/2 interventional study of Tadalafil- Tablet or Oral suspension in Pulmonary Arterial Hypertension, sponsored by Eli Lilly and Company. Completed at 16 sites in 6 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2019-10-09.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Enrollment
169th of 253
20 · median 40
Started
2012
with 13 others
Phase 1/2
7 of 312
2 open now
Registered
111th of 312
by date

Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 169th largest by enrollment of the 253 interventional ones that give a count, is one of 14 that started in 2012, is one of 7 in phase 1/2, and was the 111th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to see how much study drug is in the blood of children with pulmonary arterial hypertension (PAH) after dosing to establish the correct dose for further clinical research.

Read the detailed description

During Period I, tadalafil will be administered orally, once daily, at a low dose for approximately 5 weeks followed by a high dose for approximately 5 weeks. Dose levels are calculated based on body weight cohorts. Heavy weight cohort >=40 kg, middle weight cohort >=25 kg to \<40 kg. Light weight cohort\<25 kg. Participants who complete Period 1 may continue taking tadalafil in Period 2 for at least 2 years. Starting dose will not exceed the maximum weight range dose established in Period 1 and after the first 3 months of Period 2, the dose may be adjusted based on available safety and efficacy information.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently have a diagnosis of PAH that is either:

    • idiopathic (including hereditary), related to collagen vascular disease, related to anorexigen use, associated with surgical repair, of at least 6 month duration, of a congenital systemic to pulmonary shunt (for example, atrial septal defect, ventricular septal defect, patent ductus arteriosus).
  • Have a history of the diagnosis of PAH established by a resting mean pulmonary artery pressure ≥25 mm Hg, pulmonary artery wedge pressure ≤15 mm Hg, and a pulmonary vascular resistance (PVR) ≥3 Wood units via right heart catheterization. In the event that a pulmonary artery wedge pressure is unable to be obtained during right heart catheterization, participants with a left ventricular end diastolic pressure \<15 mm Hg, with normal left heart function, and absence of mitral stenosis on echocardiography can be eligible for enrollment
  • Have a World Health Organization (WHO) functional class value of I, II or III at the time of enrollment

Exclusion criteria

Exclusion Criteria:

  • Have pulmonary hypertension related to conditions other than specified above, including but not limited to chronic thromboembolic disease, portal pulmonary hypertension, left-sided heart disease or lung disease and hypoxia
  • History of left-sided heart disease, including any of the following:

    • (pulmonary artery occlusion pressure [PAOP] 15 to 18 mm Hg) aortic or mitral valve disease (that is, aortic stenosis, aortic insufficiency, mitral stenosis, moderate or greater mitral regurgitation)
    • pericardial constriction
    • restrictive or congestive cardiomyopathy
    • \<40% by multigated radionucleotide angiogram (MUGA), angiography, or echocardiography
    • left ventricular shortening fraction \<22% by echocardiography
    • life-threatening cardiac arrhythmias
    • symptomatic coronary artery disease within 5 years of study entry as determined by the physician
  • History of atrial septostomy or Potts Shunt within 3 months before administration of study drug
  • Unrepaired congenital heart disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Tadalafil

    Light Weight \<25 kg Period 1: 2 milligram (mg) or 4 mg tadalafil administered once daily (QD) in oral suspension formulation for 5 weeks then 8 mg,10 mg,15 mg or 20 mg tadalafil was administered QD in oral suspension formulation for 5 weeks. Middle Weight: 25 kg to \<40 kg Period 1: 5 mg tadalafil tablet administered QD for 5 weeks then 10 mg, 15 mg or 20 mg tablet tadalafil administered QD for 5 weeks. Heavy: ≥40 kg Period 1: 10 mg tadalafil tablet administered QD for 5 weeks then 20 mg or 40 mg tablet tadalafil administered QD for 5 weeks.

    Drug: Tadalafil- Tablet or Oral suspension

Interventions

  • Tadalafil Tablets administered orally. Tadalafil Oral suspension: An aqueous, ready-to-use suspension for oral administration.

    Also known as: LY450190

06

What researchers measure

Primary outcomes

  1. Population Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil

    Population Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil. The measure of dispersion reported is 90% Prediction Intervals and not Confidence Intervals.

    Time frame: Period 1: Pre Dose and 2, 4, 8, 12, and 24 Hours Post Dose on Days 1, 14 and 49; with single dose measures on Day 1 and steady-state measurements on Days 14 and 49

  2. Population Pharmacokinetics: Average Concentration (Cmean,ss) of for Tadalafil at Steady-State.

    Population Pharmacokinetics: Average Concentration (Cmean,ss) of for tadalafil at steady-state. The measure of dispersion reported is 90% Prediction Intervals and not Confidence Intervals.

    Time frame: Period 1: Pre Dose and 2, 4, 8, 12, and 24 Hours Post Dose on Days 1, 14 and 49; with single dose measures on Day 1 and steady-state measurements on Days 14 and 49

Secondary outcomes

  1. Percentage of Participants With Clinical Worsening

    Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).

    Time frame: Baseline Up to 27 Months

  2. Number of Participants With Palatability of the Tadalafil Suspension

    The Taste Assessment Questionnaire (TAQ) questions were: TAQRES1: Please rate the bitterness level. TAQRES2: Please rate the sweetness level. TAQRES3: Please rate the aftertaste. TAQRES4: Please rate the overall acceptability of the taste for daily use.

    Time frame: Day 35 (high dose)

07

Results

Posted Feb 5, 2019

Participant flow

Per protocol, the summary was based on weight cohorts.

Period 1: Low Dose
Participant flow — Period 1: Low Dose
MilestoneLight Weight <25 kgMiddle Weight: 25 kg to <40 kgHeavy Weight: ≥40 kg
Started676
Received 2 mg100
Received 4 mg500
Received 5 mg070
Received 10 mg006
Completed676
Not completed000
Period 1: High Dose
Participant flow — Period 1: High Dose
MilestoneLight Weight <25 kgMiddle Weight: 25 kg to <40 kgHeavy Weight: ≥40 kg
Started676
Received 8 mg100
Received 10 mg110
Received 15 mg110
Received 20 mg351
Received 40 mg005
Completed666
Not completed010
Withdrew: Physician decision010
Period 2
Participant flow — Period 2
MilestoneLight Weight <25 kgMiddle Weight: 25 kg to <40 kgHeavy Weight: ≥40 kg
Started666
Received 7 mg100
Received 7.5 mg020
Received 8 mg100
Received 10 mg010
Received 15 mg121
Received 20 mg314
Received 40 mg001
Completed554
Not completed112
Withdrew: Death011
Withdrew: Physician decision001
Withdrew: Non-compliance with study drug100

Outcome measures

PrimaryPopulation Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil

Population Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil. The measure of dispersion reported is 90% Prediction Intervals and not Confidence Intervals.

Time frame:
Period 1: Pre Dose and 2, 4, 8, 12, and 24 Hours Post Dose on Days 1, 14 and 49; with single dose measures on Day 1 and steady-state measurements on Days 14 and 49
Reported as:
Median · nanograms* hour per milliliter(ng*hr/mL)
Population Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil
nanograms* hour per milliliter(ng*hr/mL)20 mg Light Weight: <25 kg20 mg Middle Weight: 25 kg to <40 kg40 mg Heavy Weight: ≥40 kg
Not Taking Bosentan8170 (3850 to 16700)8390 (4130 to 18400)15200 (6980 to 31100)
Taking Concomitant Bosentan4550 (2170 to 9450)5000 (2440 to 10600)8990 (4270 to 19500)
PrimaryPopulation Pharmacokinetics: Average Concentration (Cmean,ss) of for Tadalafil at Steady-State.

Population Pharmacokinetics: Average Concentration (Cmean,ss) of for tadalafil at steady-state. The measure of dispersion reported is 90% Prediction Intervals and not Confidence Intervals.

Time frame:
Period 1: Pre Dose and 2, 4, 8, 12, and 24 Hours Post Dose on Days 1, 14 and 49; with single dose measures on Day 1 and steady-state measurements on Days 14 and 49
Reported as:
Median · nanograms per milliliter (ng/mL)
Population Pharmacokinetics: Average Concentration (Cmean,ss) of for Tadalafil at Steady-State.
nanograms per milliliter (ng/mL)20 mg Light Weight <25 kg20 mg Middle Weight: 25 kg to <40 kg40 mg Heavy Weight: ≥40 kg
Not Taking Bosentan340 (161 to 694)350 (172 to 767)633 (291 to 1300)
Taking Concomitant Bosentan190 (90.4 to 394)209 (102 to 440)375 (178 to 815)
SecondaryPercentage of Participants With Clinical Worsening

Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).

Time frame:
Baseline Up to 27 Months
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Worsening
percentage of participantsLight Weight <25 kgMiddle Weight: 25 kg to <40 kgHeavy Weight: ≥40 kg
Percentage of Participants With Clinical Worsening50.0028.5733.33
SecondaryNumber of Participants With Palatability of the Tadalafil Suspension

The Taste Assessment Questionnaire (TAQ) questions were: TAQRES1: Please rate the bitterness level. TAQRES2: Please rate the sweetness level. TAQRES3: Please rate the aftertaste. TAQRES4: Please rate the overall acceptability of the taste for daily use.

Time frame:
Day 35 (high dose)
Reported as:
Count of participants · Participants
Number of Participants With Palatability of the Tadalafil Suspension
ParticipantsLight Weight: <25 kg
TAQRES1: Extremely bitter0
TAQRES1: Very bitter0
TAQRES1: Moderately bitter0
TAQRES1: Slightly bitter0
TAQRES1: Not bitter3
TAQRES2: Extremely sweet1
TAQRES2: Very sweet0
TAQRES2: Moderately sweet1
TAQRES2: Slightly sweet1
TAQRES2: Not sweet0
TAQRES3: Extreme aftertaste0
TAQRES3: Strong aftertaste1
TAQRES3: Moderate aftertaste0
TAQRES3:Slight aftertaste0
TAQRES3:No aftertaste2
TAQRES4: Not acceptable0
TAQRES4: Slightly acceptable0
TAQRES4: Acceptable2
TAQRES4: Very acceptable1

Adverse events

Collected over Up To 27 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Light Weight: <25 kg0/6 (0%)1/6 (16.7%)6/6 (100%)
Middle Weight: 25 kg to <40 kg1/7 (14.3%)4/7 (57.1%)7/7 (100%)
Heavy Weight: ≥40 kg1/6 (16.7%)3/6 (50%)6/6 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventLight Weight: <25 kgMiddle Weight: 25 kg to <40 kgHeavy Weight: ≥40 kg
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders1/61/72/6
Ovarian cystReproductive system and breast disorders0/40/51/4
Pneumonia viralInfections and infestations1/60/70/6
Viral infectionInfections and infestations0/61/71/6
PresyncopeNervous system disorders1/60/70/6
SyncopeNervous system disorders1/60/70/6
Cardiac failureCardiac disorders0/61/70/6
GastritisGastrointestinal disorders0/61/70/6
PyrexiaGeneral disorders0/61/70/6
Type 1 diabetes mellitusMetabolism and nutrition disorders0/61/70/6
Most frequent other events
Showing 10 of 97
Most frequent other events
EventLight Weight: <25 kgMiddle Weight: 25 kg to <40 kgHeavy Weight: ≥40 kg
GastroenteritisInfections and infestations3/60/71/6
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/63/70/6
Angina pectorisCardiac disorders1/60/72/6
Ear painEar and labyrinth disorders0/60/72/6
VomitingGastrointestinal disorders2/62/71/6
PyrexiaGeneral disorders2/61/71/6
BronchitisInfections and infestations2/61/70/6
NasopharyngitisInfections and infestations2/61/72/6
Respiratory tract infectionInfections and infestations0/60/72/6
HeadacheNervous system disorders2/62/72/6

Baseline characteristics

Participants who received at least one dose of study drug. Participants were first administered a low dose to explore PK of tadalafil and determine a high dose within the weight cohort. Per protocol, the summary was based on weight cohorts.

Age, Continuous
Age, Continuous(years)Light Weight: <25 kgMiddle Weight: 25 kg to <40 kgHeavy Weight: ≥40 kgTotal
Mean5.00 (2.5 to 8.0)10.91 (7.3 to 17.9)14.45 (11.3 to 17.6)10.16 (2.5 to 17.9)
Sex: Female, Male
Sex: Female, Male(Participants)Light Weight: <25 kgMiddle Weight: 25 kg to <40 kgHeavy Weight: ≥40 kgTotal
Female45413
Male2226
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Light Weight: <25 kgMiddle Weight: 25 kg to <40 kgHeavy Weight: ≥40 kgTotal
American Indian or Alaska Native1001
Asian0213
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White45514
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Light Weight: <25 kgMiddle Weight: 25 kg to <40 kgHeavy Weight: ≥40 kgTotal
Canada3115
United States1012
Poland1225
United Kingdom0303
France0112
Spain1012
08

Study locations

16 sites
  • Children's Hospital of Colorado
    Aurora, Colorado 80045, United States
  • Children's Heathcare of Atlanta, Inc. at Egleston
    Atlanta, Georgia 30322, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202-5225, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205-2664, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Montreal, Quebec H3T 1C5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Toronto, M5G 1X8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13385, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75743, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toulouse, 31026, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-952, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warszawa, 00-576, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warszawa, 04-730, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28041, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bloomsbury, London WC1N 3JH, United Kingdom
09

References and documents

Publications

  • Ferguson-Sells L, Velez de Mendizabal N, Li B, Small D. Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model. Clin Pharmacokinet. 2022 Feb;61(2):249-262. doi: 10.1007/s40262-021-01052-8. Epub 2021 Aug 11. PubMed 34379314 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2012 to primary completion in Apr 2017, 57 months.

Results were first posted in Feb 2019, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2011
First posted
Dec 2, 2011
StartActual
Jul 17, 2012
Primary completionActual
Apr 21, 2017
CompletionActual
Apr 3, 2019
Results first posted
Feb 5, 2019
Last update
Oct 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01484431
Responsible party
Sponsor
First posted
Dec 2, 2011
Start date
Jul 17, 2012
Primary completion
Apr 21, 2017
Completion
Apr 3, 2019
Results posted
Feb 5, 2019
Last update
Oct 9, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion